Coherus BioSciences (NASDAQ:CHRS) Given “Buy” Rating at HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $12.00 price target on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the company. StockNews.com lowered Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. UBS Group downgraded Coherus BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $4.00 to $1.50 in a research note on Friday, August 16th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.13.

Coherus BioSciences Price Performance

Shares of NASDAQ:CHRS opened at $0.72 on Thursday. The company has a market capitalization of $83.39 million, a P/E ratio of -1.81 and a beta of 0.69. Coherus BioSciences has a 1-year low of $0.66 and a 1-year high of $3.70. The firm’s 50 day simple moving average is $1.02 and its two-hundred day simple moving average is $1.47.

Coherus BioSciences (NASDAQ:CHRS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $64.98 million for the quarter, compared to analysts’ expectations of $57.08 million. On average, sell-side analysts anticipate that Coherus BioSciences will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coherus BioSciences

Hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in Coherus BioSciences by 2,672.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 19,912 shares during the last quarter. TIAA Trust National Association bought a new stake in Coherus BioSciences in the second quarter worth $47,000. Bayesian Capital Management LP purchased a new stake in Coherus BioSciences during the first quarter valued at $56,000. Price T Rowe Associates Inc. MD lifted its position in Coherus BioSciences by 32.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 7,608 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Coherus BioSciences in the 1st quarter worth $94,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.